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LH-stimulated adenylate cyclase activity in membrane preparations of bovine luteal cells could be enhanced by treating the cells with either 
phospholipase D or its hydrolysis product, phosphatidic acid. Similar augmentary effects were also produced following treatment of the cells with 
EGF. Moreover, EGF could stimulate the formation of [3H]phosphatidic a id in [3H]myristic acid preloaded cells, suggesting that EGF is able to 
activate cellular phospholipase D. Also, PMA was able to increase the phosphatidic acid formation with a parallel increase in the adenylate cyclase 
activity. We propose, therefore, that phosphatidic acid may act as an intracellular second messenger linking EGF-mediated activation of phospho- 
lipase D with the sensitization of LH receptor-coupled a enylate cyclase signalling system. 
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1. INTRODUCTION 
Ligands that activate phosphatidyl inositol-specific 
phospholipase C and protein kinase C often also modu- 
late the adenylate cyclase signalling pathway in the tar- 
get cells [1 3]. In one report, a direct inhibitory effect 
of exogenously added phosphatidyl choline-specific 
phospholipase C from Bacil lus cereus on adenylate 
cyclase activity has been demonstrated in 3T3 fibro- 
blasts [4]. In ovarian steroidogenic ells, adenylate 
cyclase signalling pathway is of primary importance 
since both the process of differentiation and ster- 
oidogenesis are under the control of hormones that ele- 
vate cyclic AMP contents of the cells. Thus crosstalks 
with other signal transduction pathways which result in 
the modulation of hormone receptor-coupled a enylate 
cyclase system can be of major consequence in the reg- 
ulation of various differentiated cell functions. In the 
case of bovine luteal cells, we have previously demon- 
strated that pretreatment of the cells with either phorbol 
ester, PMA [7], or EGF [8] resulted in an augmentation 
of forskolin-stimulated a enylate cyclase activity in 
these cells. 
The recent recognition of the importance of phospho- 
lipase D in signal transduction mechanisms [9,10] 
prompted us to examine the potential role of the phos- 
pholipase D-linked mechanism on the EGF-mediated 
augmentation of luteal adenylate cyclase activity. We 
report here that exogenous phospholipase D can en- 
hance the LH-stimulated adenylate cyclase activity and 
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that EGF is in a position to activate the endogenous 
phospholipase D in luteal cells, and propose that its 
enzymatic hydrolysis product, phosphatidic acid, may 
represent a new link between the ligand-activated EGF 
receptor and the sensitization of the gonadotrophin re- 
ceptor-linked adenylate cyclase system. 
2. MATERIALS AND METHODS 
2. i. Preparation of cells and incubation procedure 
Bovine luteal cells were isolated and purified as described previously 
[7,11]. Incubations of cells (200,000) were routinely carried out in 
500 ,ul minimum essential medium containing 25 mM HEPES, pH 7.4, 
and 0.1% bovine serum albumin (medium) at 37°C for the indicated 
durations without any addition or with either 10 ng/ml EGF (Boehrin- 
ger-Mannheim, Mannheim), 10 nM 4fl phorbol myristate acetate, 
PMA (Sigma, Deisenhofen) or 2 U/ml phospholipase D from Strepto- 
myces chromofuscus (Sigma), unless otherwise indicated. The cell pel- 
lets were stored frozen at -80°C for further analysis. 
2.2. Preparation of the luteal cell membrane fraction 
The cell pellet was thawed and homogenized in a Dounce-type all 
glass homogenizer in 1 ml 10 mM Tris-HCl, pH 7.4, containing 1mM 
dithiothreitol (buffer A) supplemented with the following protease 
inhibitors (all from Sigma, Deisenhofen): 10/lg/ml eupeptin, 1¢zg/ml 
pepstatin, l ,ug/ml amastatin followed by ultrasonication i  a Branson 
Sonifier B12, twice for 10 s each at a power setting 2. Immediately, 
thereafter sucrose solution was added to a final sucrose concentration 
of 0.25 mM. The homogenate was centrifuged at 200 x g for 15 min 
at 4°C. The supernatant obtained was recentrifuged at40,000 x g for 
60 min at 4°C. The pellet obtained was resuspended in buffer A and 
was used as luteal membrane fraction. Protein content was determined 
as described in [12]. 
2.3. Adenylate cyclase assay 
The enzyme assay was carried out in a final volume of 100/11 at 36°C 
for 15 rain. The standard incubation mixture [8] consisted of 40 mM 
Tris-HC1, pH 7.5, 1 mM EDTA, 0.5 mM 3-isobutyl-l-methyl xan- 
thine, 1 mM ATE 10 mM creatine phosphate, 13.2 U/ml creatine 
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phosphokinase (all reagents from Sigma) and 10 pg protein equivalent 
of membrane fraction. Where indicated, Forskolin (Calbiochem, Bad 
Sodem, Germany) or bovine LH (a generous gift from NIH, 
NIADDK, Bethesda, MD) was added. The incubation was terminated 
by adding 1 ml ice-cold 100% ethanol. The amount of cAMP formed 
was measured by a specific radioimmunoassay [7,8]. 
2.4. In vitro treatments of luteal membrane fraction 
The membrane fraction (80 ¢tg protein) was incubated in 100 ¢tl 
PIPES buffer, pH 7.0, in the presence of 10 mM MgCI2, 50/IM CaC12, 
50#M EGTA, 100HM ATP, without any other addition or with either 
100 HM phosphatidic acid (arachidonic/stearic acid, Sigma, Deisen- 
hofen), 10 ng/ml EGF or 10 nM PMA for 10 min. At the end of the 
incubation, the tubes were placed in an ice water bath. The samples 
were immediately centrifuged at 40,000 x g for 60 rain. The resulting 
pellet was resuspended and after determination f its protein content, 
was used in the adenylate cyclase assay. 
2.5. Lipid analysis' 
Cells were labelled for 3 h with 5 ¢tCi [3H]myristic acid (specific 
activity 54 Ci/mmol, Amersham, Braunschweig) in 500 pl medium and 
were collected by centrifugation at 100 x g for 15 min and washed 
thrice with 500 ,ul medium each time. The cells were then loaded for 
5 min with 1.5 mM CaCI 2 and 50pM cytochalasin B [13] before adding 
the agonists. Cells were then stimulated with EGF or PMA for 1 min 
and the incubation was stopped by placing the tubes in an ice water 
bath and rapidly adding 10 ¢tl conc. HC1. The cell extracts were 
transferred to Eppendorf tubes for lipid analysis [14]. Briefly, the 
samples were layered with 0.25 ml methanol followed by 0.5 ml chlo- 
roform and finally 0.25 ml water was added. The mixture was vortexed 
vigorously and the phases were separated by centrifugation at 
2,000 x g for 15 min. The upper phase was removed almost completely 
and discarded. The lower phase was collected and dried under nitro- 
gen flow. The dried extract was redissolved in minimum amount of 
CHCI3/CH3OH (9:1) and applied to silica gel G 60 thin layer plates 
(Whatman, LK). The plates were developed in organic phase from: 
ethyl acetate/isooctane/glacial acetic acid/water (110:50:20:100, v/v) 
[15] and the spots were located by staining the standards with iodine 
vapour and autoradiography, for which the plates were prepared for 
fluorography by spraying with EN3HANCE (DuPont NEN, Bad 
Homburg, Germany) and then exposed to film at -80°C. For quanti- 
tative estimation of 3H incorporation, the silica gel areas of interest 
were scrapped, placed in scintillation vials, extracted with 1 ml meth- 
anol/conc. HC1 (150:1 ) and counted after addition of 9 ml scintillation 
cocktail. 
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Fig. 1. Exogenous phospholipase D stimulates luteal adenylate cyclase 
activity. Luteal cells were treated for 10 min with various concentra- 
tions of phospholipase D (PLD), following which membrane fractions 
were prepared for adenylate cyclase assay, carried out for 15 min in 
the absence of any addition (©) and in the presence of 25 ¢tM forskolin 
(e) or 100 ng LH plus 1 HM GTP (A), as described in section 2. 
relevance and phospholipase D treatment does increase 
the LH/GTP-stimulated cyclase activity (Fig. 1), in all 
experiments described below adenylate cyclase has been 
measured in the presence of LH/GTP. 
Fig. 2 depicts the time course of the cyclase assay 
carried out with membranes prepared from untreated or
phospholipase D-treated cells. It is evident hat the en- 
zyme activity increased linearly with the increase in the 
duration of incubation, and that, compared to un- 
treated cells, the enzyme activity was markedly greater 
for the membrane preparation from phospholipase D-
treated cells at all time points of the assay. Furthermore, 
kinetic analysis of the enzyme activity (Fig. 3) revealed 
2.6. Data presentation 
If not otherwise stated, the results have been presented as 
mean +_ S.E. from quadruplicate determinations from one of three 
experiments performed. 
3. RESULTS 
3.1. Exogenous phospholipase D increases luteal adenyl- 
ate cyclase activity 
Pretreatment of luteal cells with various concentra- 
tions of phospholipase D led to a dose-related increase 
in basal, forskolin- and LH/GTP-stimulated adenylate 
cyclase activity measured in membranes prepared from 
the pretreated cells (Fig. 1). In separate control experi- 
ments (data not shown), the effects of phospholipase A2
and C (both phosphatidic choline- and phosphatidic 
inositol-specific) were examined but neither of these 
could enhance the adenylate cyclase activity. 
Since in luteal cells, the LH receptor-coupled a enyl- 
ate cyclase signalling pathway is of major physiological 
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Fig. 2. Time course of adenylate cyclase assay using membranes pre- 
pared from untreated and phospholipase D-treated luteal cells. The 
cells were pretreated for 10 min without any addition (©) or with 
2 U/ml phospholipase D (e). The membrane fractions were prepared 
and used in the adenylate cyclase assay, carried out for various dura- 
tions in the presence of LH/GTP (see Fig. 1 for other details). 
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Fig. 3. Effects of phospholipase D treatment on the kinetics of adenyl- 
ate cyclase activity measured in the presence of LH/GTE Membrane 
fraction was prepared from luteal cells treated for 10 min with phos- 
pholipase D (2 U/ml). Adenylate cyclase assay was carried out for 
15 min in the absence (©) or in the presence (e) of LH/GTP with 
varying concentrations of the substrate, ATE 
of [3H]phosphatidic a id was monitored by thin layer 
chromatographic separation of the products (Fig. 5A) 
and by counting the radioactivity associated with the 
silica gel area containing the phosphatidic acid spot 
(Fig. 5B). It is clear from the data shown, that both 
EGF and PMA could markedly (4- to 5-fold) increase 
the formation of phosphatidic acid. 
3.4. Stimulation of luteal adenylate cvclase activity by 
phosphatidic acid 
We have next incubated the luteal membrane prepa- 
ration in vitro with phosphatidic acid, a hydrolysis 
product of phospholipase D and show that phospha- 
tidic acid pretreatment results (Fig. 6A) in an augmenta- 
tion of the adenylate cyclase activity in a dose-depend- 
ent manner, maximum augmentation being achieved 
with 50 100 #M PA. It is evident from the data shown 
in Fig. 6B, that 100#M PA was able to augment adenyl- 
ate cyclase activity to an extent comparable with that 
caused by 10 ng/ml EGF or 10 nM PMA. 
that the preincubation with phospholipase D led to an 
increase in the Vma ~ of the enzyme from 4.1 (control 
untreated cells) to 9.8 pmol cAMP/mg protein/min 
(phospholipase D-treated cells) without affecting the Km 
value for ATE 
3.2. Comparison between the effects produced by phos- 
pholipase D with those caused by EGF on luteal 
adenylate cyclase activity 
Further, in terms of physiological relevance, it was of 
interest o determine whether an exogenous ligand will 
be in a position to activate the endogenous phospholi- 
pase D in luteal cells. In this context EGF was of inter- 
est to us, since we have previously characterized the 
receptors for EGF on these cells and have shown that 
EGF did augment forskolin-stimulated adenylate 
cyclase activity [8]. The effect of EGF on LH/GTP- 
stimulated adenylate cyclase activity in luteal cell has 
not yet been reported. We show now in Fig. 4, that 
pretreatment of luteal cells with either 10 ng/ml EGF or 
2 U/ml phospholipase D resulted in a comparable aug- 
mentation of the enzyme activity measured in the pres- 
ence of LH/GTE 
3.3. EGF stimulates phosphatidic acid formation in 
luteal cells 
Next we assessed whether phospholipase D-mediated 
phospholipid breakdown could be induced by EGF in 
luteal cells. In this experiment (Fig. 5), for the sake of 
comparison, we have also included PMA, since activa- 
tion of protein kinase C in a variety of cells is known 
to result in an activation of phospholipase D [16,17] on 
the one hand and augmentation of adenylate cyclase 
activity [1 3,7] on the other. We have preincubated the 
cells with [3H]myristic acid for 3 h and then stimulated 
with either EGF or PMA for one minute. The formation 
4. DISCUSSION 
We have presented evidence here showing that both 
exogenous phospholipase D and its hydrolysis product 
phosphatidic acid are able to augment he gonadotro- 
phin receptor-coupled adenylate cyclase activity in 
luteal cells. This effect could be mimicked by EGF, 
which was also shown to be able to stimulate intracellu- 
lar phosphatidic acid accumulation, as a sequelae to the 
activation of cellular phospholipase D. As far as we are 
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Fig. 4, EGF can mimic the augmentary effects of phospholipase D on 
LH receptor-coupled a enylate cyclase activity in luteal membrane 
preparation. The cells were treated for 10 min without (C) any addi- 
tion or with 2 U/ml phospholipase D (PLD) or 10 ng/ml EGF. The 
enzyme activity was measured in membrane fractions prepared from 
the cells. 
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Fig. 5. Increase in phosphatidic acid accumulation i luteal cells fol- 
lowing treatment of the cells with EGF and PMA. The luteal cells were 
first incubated for 3 h with [3H]myristic acid, washed and were then 
exposed to either 10 ng/ml EGF or 10 nM PMA for one min. Con 
represents cells treated in the absence of the agonists. The incubation 
was stopped by placing the tubes in an ice water bath followed by the 
extraction of lipids and separation on thin layer chromatography 
plates as described in section 2. (A) The radiolabelled lipids were 
visualized by autoradiography and located by staining the standards 
with iodine vapour. The arrow indicates the position of the phospha- 
tidic acid. (B) The silica gel area corresponding to phosphatidic acid 
was scrapped and counted in a beta counter. The data represent 
mean + S.E. from three separate xperiments. 
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aware, this is the first demonstration li king the phos- 
pholipase D activation with a sensitization of a recep- 
tor-coupled adenylate cyclase signalling system. 
This stimulatory effect of EGF on luteal adenylate 
cyclase agrees well with the results previously published 
[8,18,19] and reinforce the emerging concept that a 
growth factor receptor may crosstalk with G protein- 
coupled seven-transmembrane-domain receptors linked 
to cAMP signalling pathway. Also the link between the 
activation of protein kinase C and the adenylate cyclase 
system has been documented in luteal [7] and other cells 
[1-3]. It appears that in luteal cells at least two signals 
are required for full activation of the gonadotrophin 
receptor-coupled a enylate cyclase. The first signal, for 
example EGF in this case, activates a phospholipase D 
pathway resulting in the formation of phosphatidic acid 
which in turn sensitizes the adenylate cyclase system for 
an optimal stimulation through the second signal, LH. 
The activation ofphospholipase D by EGF and PMA 
as observed in luteal cells, has been well documented in
a variety of other cells [16,17,20,21]. However, our re- 
sults differ from previous observations in other cell 
types [22,23], where the products of phospholipase D 
were reported to have an inhibitory influence on adenyl- 
ate cyclase activity. This difference may be explained by 
the fact that such effects vary in a cell- or tissue-specific 
manner. For example, recently evidence has indeed be- 
come available showing that the manner in which the 
activation of protein kinase C would affect the adenyl- 
ate cyclase activity in a particular cell type depends 
upon the specific types of adenylate cyclase present in 
that particular cell [24,25]. 
In conclusion, we propose that the phosphatidic acid 
accumulated as a result of the activation of phospholi- 
pase D, after treatment of the cells with EGF or PMA, 
serves as an intracellular second messenger which is able 
to upregulate the LH receptor-coupled adenylate 
cyclase in luteal cells. A second messenger [26] and 
growth factor-like [27] role has been previously pro- 
posed for phosphatidic acid; however, its role as a link 
between the signalling mechanisms associated with the 
single transmembrane domain tyrosine kinase-linked 
receptor and the seven transmembrane domain adenyl- 
ate cyclase-linked receptors has not been previously rec- 
ognized. Whether phosphatidic acid itself modulates the 
adenylate cyclase or its effect is mediated via a specific 
kinase, as suggested recently [28], remains the subject 
for future investigation. 
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Fig. 6. Prior treatment of lutea] membranes with phosphatidic acid 
leads to a stimulation of adenylate cyclase. (A) The membrane frac- 
tions were incubated as described in section 2 with various concentra- 
tions of phosphatidic acid (PA) for 10 min. The incubation was 
stopped by placing the tubes in an ice water bath. The samples were 
immediately centrifuged at40,000 x g for 60 min at 4°C. The resulting 
pellets were used for adenylate cyclase assay in the presence of LH/ 
GTR (B) The membrane fraction was incubated without any addition 
(C) or with either 100 ,uM phosphatidic acid (PA), 10 ng/ml EGF or 
10 nM PMA and assayed for adenylate cyclase activity as above. 
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